Your Expert in Oligonucleotide Therapeutics

At Xoligo Biologics, we exist at the sharp edge of the nucleic acid revolution. With operations in Montreal, Canada and Cambridge, Massachusetts, we are one of the few pure-play CDMOs dedicated entirely to mRNA and nucleic acid therapeutics. Where most CDMOs are locked inside sprawling service portfolios, we focus with intent—building the specialized infrastructure and scientific depth needed to accelerate the next wave of RNA medicines.

Our Focus

The world learned the power of mRNA during the pandemic. Today, its reach extends far beyond vaccines—into cancer immunotherapies, rare disease treatments, and protein replacement strategies. Xoligo supports this expanding frontier by delivering:

• RNA Synthesis – High-fidelity production of mRNA, saRNA, circRNA, and DNA plasmids.
• LNP Formulation – Cutting-edge lipid nanoparticle systems designed for precise delivery.
• GMP Release & Analytics – Rigorous quality control and regulatory alignment for global readiness.

Our Value

Few CDMOs are purpose-built for RNA. The largest players—Lonza, Catalent, WuXi—are encumbered by scale, politics, and competing priorities. Xoligo Biologics was created differently: an agile, innovation-first partner dedicated to the modalities with the fastest growth and highest unmet need. By concentrating on RNA platforms and their enabling technologies, we provide sharper focus, faster timelines, and a partner that understands the science as deeply as the business.

Looking Ahead

The nucleic acid era is still being written. Whether enabling mRNA and plasmid therapeutics, or supporting viral vectors and exosomes—the critical choke points in tomorrow’s gene therapy supply chains—Xoligo Biologics is here to build what’s next.

Xoligo Biologics. Precision RNA. Purpose-built CDMO.